BACKGROUND: Cullin1 and MMP-2 have been identified as important markers in various cancers, but their roles in colorectal cancer (CRC) have remained to be discovered. The aim of this study was to investigate the expression pattern and significance of Cullin1 and MMP-2 in CRC.
METHODS: A total of 470 CRC patients were enrolled. Archival paraffin-embedded CRC tissue samples were used to generate tissue microarray blocks, which were immunohistochemically stained for Cullin1 and MMP-2. Prognostic and predictive role of Cullin1 and MMP-2 expression was evaluated by univariate and multivariate analysis, respectively. Values of p < 0.05 were considered statistically significant.
RESULTS: Cullin1 and MMP-2 protein levels were significantly upregulated in CRC tissues compared with adjacent noncancerous tissues. High tumoral Cullin1 or MMP-2 expression significantly correlated with shorter overall survival (OS), as well as with clinicopathologic characteristics in patients. Multivariate regression analysis showed that high Cullin1 and MMP-2 expressions, separately and together, were independent negative markers of OS.
CONCLUSION: Cullin1 and MMP-2 expressions could be novel diagnostic and prognostic markers for CRC patients.
ChenW., ZhengR., BaadeP.D., ZhangS., ZengH., BrayF., JemalA., YuX.Q. and HeJ., Cancer statistics in China, 2015, CA Cancer J Clin66 (2016), 115-132.
2.
YamadaA., HorimatsuT., OkugawaY., NishidaN., HonjoH., IdaH., KouT., KusakaT., SasakiY., YagiM., HigurashiT., YukawaN., AmanumaY., KikuchiO., MutoM., UenoY., NakajimaA., ChibaT., BolandC.R. and GoelA., Serum miR-21, miR-29a, and miR-125b are promising biomarkers for the early detection of colorectal neoplasia, Clin Cancer Res21 (2015), 4234-4242.
3.
SiegelR.L., MillerK.D. and JemalA., Cancer statistics, 2015, CA Cancer J Clin65 (2015), 5-29.
4.
HynesR.O., Metastatic potential: Generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell113 (2003), 821-823.
5.
PantelK., Alix-PanabieresC. and RiethdorfS., Cancer micrometastases, Nat Rev Clin Oncol6 (2009), 339-351.
6.
KessenbrockK., PlaksV. and WerbZ., Matrix metalloproteinases: Regulators of the tumor microenvironment, Cell141 (2010), 52-67.
7.
RoyR., YangJ. and MosesM.A., Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer, J Clin Oncol27 (2009), 5287-5297.
8.
MookO.R., FrederiksW.M. and Van NoordenC.J., The role of gelatinases in colorectal cancer progression and metastasis, Biochim Biophys Acta1705 (2004), 69-89.
9.
ButkiewiczD., KrzesniakM., DrosikA., GiglokM., Gdowicz-KlosokA., KosarewiczA., RusinM., MaslykB., Gawkowska-SuwinskaM. and SuwinskiR., The VEGFR2, COX-2 and MMP-2 polymorphisms are associated with clinical outcome of patients with inoperable non-small cell lung cancer, Int J Cancer137 (2015), 2332-2342.
10.
OshimaT., KunisakiC., YoshiharaK., YamadaR., YamamotoN., SatoT., MakinoH., YamagishiS., NaganoY., FujiiS., ShiozawaM., AkaikeM., WadaN., RinoY., MasudaM., TanakaK. and ImadaT., Clinicopathological significance of the gene expression of matrix metalloproteinases and reversion-inducing cysteine-rich protein with Kazal motifs in patients with colorectal cancer: MMP-2 gene expression is a useful predictor of liver metastasis from colorectal cancer, Oncol Rep19 (2008), 1285-1291.
11.
WaasE.T., WobbesT., RuersT., LommeR.M. and HendriksT., Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease, Eur J Surg Oncol32 (2006), 756-763.
12.
ShiM., YuB., GaoH., MuJ. and JiC., Matrix metalloproteinase 2 overexpression and prognosis in colorectal cancer: A meta-analysis, Mol Biol Rep40 (2013), 617-623.
13.
ZhengN., SchulmanB.A., SongL., MillerJ.J., JeffreyP.D., WangP., ChuC., KoeppD.M., ElledgeS.J., PaganoM., ConawayR.C., ConawayJ.W., HarperJ.W. and PavletichN.P., Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex, Nature416 (2002), 703-709.
14.
NakayamaK.I. and NakayamaK., Ubiquitin ligases: Cell-cycle control and cancer, Nat Rev Cancer6 (2006), 369-381.
15.
SalonC., BrambillaE., BrambillaC., LantuejoulS., GazzeriS. and EyminB., Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: Relationships with CAND1 and cyclin E protein levels, J Pathol213 (2007), 303-310.
16.
BaiJ., YongH.M., ChenF.F., MeiP.J., LiuH., LiC., PanZ.Q., WuY.P. and ZhengJ.N., Cullin1 is a novel marker of poor prognosis and a potential therapeutic target in human breast cancer, Ann Oncol24 (2013), 2016-2022.
17.
WangW., ChenY., DengJ., ZhouJ., GuX., TangY., ZhangG., TanY., GeZ., HuangY., WangS., ZhouJ., ZhouY. and ZhouS., Cullin1 is a novel prognostic marker and regulates the cell proliferation and metastasis in colorectal cancer, J Cancer Res Clin Oncol141 (2015), 1603-1612.
18.
WangS., WuX., ChenY., ZhangJ., DingJ., ZhouY., HeS., TanY., QiangF., BaiJ., ZengJ., GongZ., LiA., LiG., RoeO.D. and ZhouJ., Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer, Clin Cancer Res18 (2012), 2987-2996.
19.
WeichertW., RöskeA., GekelerV., BeckersT., EbertM.P.A., ProssM., DietelM., DenkertC. and RökenC., Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: A retrospective analysis, The Lancet Oncology9 (2008), 139-148.
20.
EdgeS.B. and ComptonC.C., The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM, Ann Surg Oncol17 (2010), 1471-1474.
21.
ZhangQ., ChenQ., LuX., ZhouZ., ZhangH., LinH.Y., DuanE., ZhuC., TanY. and WangH., CUL1 promotes trophoblast cell invasion at the maternal-fetal interface, Cell Death Dis4 (2013), e502.
22.
DealyM.J., NguyenK.V., LoJ., GstaigerM., KrekW., ElsonD., ArbeitJ., KipreosE.T. and JohnsonR.S., Loss of Cul1 results in early embryonic lethality and dysregulation of cyclin E, Nat Genet23 (1999), 245-248.
23.
BaiJ., ZhouY., ChenG., ZengJ., DingJ., TanY., ZhouJ. and LiG., Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer, Hum Pathol42 (2011), 375-383.
24.
ChenG., ChengY., MartinkaM. and LiG., Cul1 expression is increased in early stages of human melanoma, Pigment Cell Melanoma Res23 (2010), 572-574.
25.
DenicourtC. and DowdyS.F., Cip/Kip proteins: More than just CDKs inhibitors, Genes and Development18 (2004), 851-855.
26.
EgebladM. and WerbZ., New functions for the matrix metalloproteinases in cancer progression, Nat Rev Cancer2 (2002), 161-174.
27.
DongW., LiH., ZhangY., YangH., GuoM., LiL. and LiuT., Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer, Acta Biochim Biophys Sin (Shanghai)43 (2011), 840-848.
28.
UhlmannM.E., GeorgievaM., SillM., LinnemannU. and BergerM.R., Prognostic value of tumor progression-related gene expression in colorectal cancer patients, J Cancer Res Clin Oncol138 (2012), 1631-1640.
29.
HilskaM., RobertsP.J., CollanY.U., LaineV.J., KossiJ., HirsimakiP., RahkonenO. and LaatoM., Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer, Int J Cancer121 (2007), 714-723.
30.
LangenskioldM., HolmdahlL., FalkP. and IvarssonM.L., Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer, Int J Colorectal Dis20 (2005), 245-252.
31.
FanY.C., ZhuY.S., MeiP.J., SunS.G., ZhangH., ChenH.F., ChenC. and MiaoF.A., Cullin1 regulates proliferation, migration and invasion of glioma cells, Med Oncol31 (2014), 227.
32.
LibraM., ScalisiA., VellaN. et al., Uterine cervical carcinoma: Role of matrix metalloproteinases (Review), International Journal of Oncology34 (2009).
33.
ChaudharyA.K., PandyaS., GhoshK. and NadkarniA., Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: An overview, Mutat Res753 (2013), 7-23.
